Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced new positive AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and…
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab)…
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference…
New drug class prevents key ageing mechanism in organ transplants
A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs. The pioneering research, presented today at the European…
National Jewish Health Appoints Evan Zucker as Chair of Board of Directors
Evan Zucker has been named Chair of the National Jewish Health Board of Directors. He succeeds Steven D. Kris, who has been board chair since January 2020, and will continue to serve as a member of the board and executive…
Shaking Up Heart Transplant Eligibility: The Role of ‘Zombie’ Cells
A research team led by Dr. Gavin Richardson at Newcastle University is pioneering a study on ‘Zombie’ cells that could challenge existing practices in heart transplantation. The aim is to broaden the pool of available donor hearts, potentially bringing hope…
Chemotherapy before surgery reduces risk of colon cancer recurrence, finds Cancer Research UK-funded trial
Administering chemotherapy before surgery can significantly reduce the risk of colon cancer recurrence, according to a Cancer Research UK-funded trial. The FOxTROT trial, led by the University of Birmingham and the University of Leeds, involved 1,053 colon cancer patients from…
